Scientific Program

Preliminary Program

Thursday, June 28, 2018

15:00 - 15:20	Welcome Address Clyde Yancy, Northwestern University, Feinberg School of Medicine, USA
15:20 - 16:50	SYMPOSIUM: ATRIAL FIBRILLATION – DETECTION, ASSESSING THE RISK AND TREATMENT 25%-30% of all ischemic strokes are of cardio-embolic origin where 45% are related to Atrial Fibrillation (AF). Strokes due to AF are devastating ones with high rates of mortality and disability. Therefore, detecting AF, assessing the stroke risk and tailoring the right preventive treatment to an individual patient is extremely important. This session will highlight and discuss all these important issues. Chairs: Clyde Yancy, Northwestern University, Feinberg School of Medicine, USA Shyam Prabhakaran, Northwestern University, USA
	Advances in Detection of AF James Reiffel, Columbia University, USA Assessing Stroke Risk in Patients with AF Hooman Kamel, Weill Cornell Medical Center, USA Stroke Prevention in AF: The Role of Target-Specific Oral Anticoagulants Jonathan Halperin, Mount Sinai Medical Center, US. Panel Discussion
16:50 - 17:00	Short break
17:00 - 18:25	SYMPOSIUM: ATRIAL CARDIOMYOPATHY Although AF is the widely discussed issue of cardio-embolic strokes other pathological conditions of the left atrium may be important as a source of embolism. This symposium will shed light on the so far "neglected" topic in cardio-embolic stroke. Chairs: Jonathan Halperin, Mount Sinai Medical Center, USA Clifford Kavinsky, Rush University Medical Center, USA
	Atrial Cardiomyopathy Diagnostic Approaches David Tirschwell, University of Washington Medicine Comprehensive Stroke Center, USA Fibrotic Atrial Cardiomyopathy Jeffrey Goldberger, University of Miami Hospital, USA The Role of LAA Occlusion Devices in Stroke Prevention in Patients with AF Vivek Reddy, Mount Sinai Medical Center, USA Panel Discussion
18:25 - 18:30	Short break
18:30 - 19:00	KEYNOTE LECTURE: THE HEART FAILURE PATIENT WITH STROKE - WHAT IS IMPORTANT, WHAT IS DIFFERENT? Chairs: Natan Bornstein, Shaare Zedek Medical Center, Israel Jonathan Halperin, Mount Sinai Medical Center, USA
	Wolfram Doehner, ESC Council on Stroke; Univ.-Prof. for Interdisciplinary Stroke Research Charite, Germany
19:00	Opening Ceremony Followed by a Networking Welcome Reception

Friday, June 29, 2018

08:30 - 09:15	DEBATE SESSION: MANY OR FEW PATIENTS SHOULD UNDERGO PFO CLOSURE? Until recently PFO closure by endovascular procedure was not generally recommended. However, recently the results of 2 RTCs (CLOSE and REDUCE) and the long-term follow-up of the RESPECT trial were published. These results will have an impact on the current practice. The question now is not "should we close"? but "who to close"? This will be the scope of this debate. Moderators: Robert Hart, Mc Master University, Canada Clifford Kavinsky, Rush University Medical Center, USA
	Few Patients Defender: Brett Cucchiara, University of Pennsylvania, USA Many Patients Defender: Richard Smalling, UTHealth and Memorial Hermann Heart and Vascular Institute, USA
09:15 - 10:00	PANEL DISCUSSION: COLLABORATIVE MEDICINE Moderators: James Klaas, Mayo Clinic, USA Christopher Granger, Duke University School of Medicine, USA Wolfram Doehner, ESC Council on Stroke; Interdisciplinary Stroke Research Charite, Germany James Klaas, Assistant Professor of Neurology, Mayo Clinic, Rochester, USA Carmelo Graffagnino, Duke University School of Medicine, USA Hooman Kamel, Weill Cornell Medical Center, USA
10:00 - 10:30	Coffee Break, Exhibition & Poster Viewing
10:30 - 12:00	INTERACTIVE CASE DISCUSSION Moderators: Frances Caprio, Northwestern University, USA Milija Mijajlovic, Neurology Clinic, Clinical Center of Serbia Shadi Yaghi, Brown University, USA MingMing Ning, Harvard Medical School, USA Milija Mijajlovic, Neurology Clinic, Clinical Center of Serbia
12:00 - 12:45	DEBATE SESSION: EXTENSIVE OR LITTLE BURDEN OF ATRIAL FIBRILATION SHOULD TRIGGER TREATMENT? It is greatly accepted that patients with Embolic Stroke of Unknown Source (ESUS) should go on long-term cardiac monitoring in order to detect sub-clinical AF. However, it is still unknown what is the burden of AF that is clinically relevant to trigger treatment with anticoagulants. This debate will highlight the various opinions: "small vs. extensive" is the dilemma that will be discussed. Moderator: Farzaneh Sorond, Northwestern University, Feinberg School of Medicine, USA
	Little Burden Defender: Jeff Healey, McMaster University, Canada Extensive Burden Defender: Rod Passman, Northwestern Memorial Hospital, USA
12:45 - 14:15 13:00 - 14:00	Break, Exhibition & Poster Viewing Non-CME Industry Session organised by Abbott (not included in the main event CME/CPD credit offering)
14:15 - 14:45	KEYNOTE LECTURE: NAVIGATE ESUS TRIAL: WHAT DID WE LEARN? Chairs: Jeffrey Saver, Geffen School of Medicine at UCLA, USA Ayrton Massaro, Hospital Sirio Libanes, Head of Neurovascular Research Unit, Brazil
	Robert Hart, McMaster University, Canada
14:45 - 14:50	Short break
14:50 - 16:40	SYMPOSIUM: COGNITION AND THE HEART Cognitive impairment due to vascular pathology of the brain- Vascular Cognitive Impairment (VCI) is an important issue. Understanding the underlying and the related risk factors of VCI as well as the effect of the heart on VCI may have an impact on prevention and treatment of this condition. This symposium will discuss this issue from various aspects. Chairs: Philip Gorelick, Thorek Memorial Hospital, USA Georgios Tsivgoulis, University of Athens, Greece
	The Neurovascular Unit and Cognitive Impairment Constantino Iadecola, Feil Family Brain and Mind Research Institute, USA Hypertension, Small Vessel Disease and Cognition Ralph Sacco, Miller School of Medicine, University of Miami, USA Defining Optimal Brain Health in Adults Philip Gorelick, Mercy Health Hauenstein Neuroscience Center, USA Aortic Stenosis, TAVR and Cognition: Imaging and Clinical Findings Ronald Lazar, University of Alabama at Birmingham, USA Panel Discussion
16:40 - 17:10	Coffee Break, Exhibition & Poster Viewing
17:10 - 18:40	SYMPOSIUM: EMBOLIC STROKE OF UNDETERMINED SOURCE Stroke due to ESUS imposes difficult clinical dilemma for the treating physician. The magnitude of the problem, practical evaluation and treatment options will be discussed in this symposium. Chairs: Ralph Sacco, Miller School of Medicine, University of Miami, USA Rod Passman, Northwestern Memorial Hospital, USA

The Magnitude of the Problem
Georgios Tsivgoulis, University of Athens School of Medicine/The University of Tennessee Health Science Center, Greece/USA
Evaluation of Patients with ESUS
Jeffrey Saver, Geffen School of Medicine at UCLA, USA
Treatment options
Gustavo Saposnik, University of Toronto, Canada

Panel Discussion

Saturday, June 30, 2018

08:00-09:00	EDUCATIONAL SESSION: BRAIN RECOVERY AFTER STROKE Chair: Natan Bornstein, Shaare Zedek Medical Center, Israel Medical Therapy for Post-Stroke Motor Recovery Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel Intracardiac Hemostasis Parameters, Endothelial Damage and Their Association with Microembolization in the Fibrillating Atrium Laszlo Csiba,University Debrecen, Hungary Neuroprotection in the Reperfusion Era Jeffrey Saver, Geffen School of Medicine at UCLA, USA
09:00 - 10:30	SYMPOSIUM: ATRIAL FIBRILLATION: MISCELLANEOUS There are several practical aspects in the treatment of AF patients with AC. This session will deal with three of these important topics as listed below. Chair: Jose Biller, Loyola University Medical Center, USA Ayrton Massaro, Hospital Sirio Libanes, Head of Neurovascular Research Unit, Brazil
	How to Improve the Use of Anticoagulation for Stroke Prevention in AF Christopher Granger, Duke University School of Medicine, USA When to Start Anticoagulation after Acute Ischemic Stroke Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel Treatment of Acute Stroke in AF Patients with Mechanical Thrombectomy Gregory Albers, Stanford Stroke Center, USA Panel Discussion
10:30 - 11:00	Coffee Break, Exhibition & Poster Viewing
11:00 - 11:30	KEYNOTE LECTURE: ATRIAL FIBRILLATION AND STROKE: THE FIRST 100 YEARS Chairs: Gregory Albers, Stanford Stroke Center, USA Wolfram Doehner, Berlin Center for Regenerative Therapies (BCRT), Germany
	Robert Hart, McMaster University, Canada
11:30 - 13:00	INTERACTIVE CASE DISCUSSION Moderator: Laszlo Csiba, University Debrecen, Hungary Kevin Sheth, Yale School of Medicine, USA Eitan Auriel, Carmel Medical Center, Israel
13:00 - 14:00	Break, Exhibition & Poster Viewing
14:00 - 15:50	SYMPOSIUM: AF AND ICH Anticoagulants (AC) are the treatment of choice for stroke prevention in AF patients. However, AC carries a risk of bleeding and especially of Intra-Cerebral Hemorrhage (ICH). Therefore, stroke prevention, acute stroke treatment of AF patients with Mechanical Thrombectomy and when to resume AC after ICH is of a major concern for the treating physician. This symposium will try to clarify these complex and problematic issues. Chairs: Mahmut Edip Gurol, Massachusetts General Hospital Harvard Medical School, USA James Conners, Rush University Medical Center, USA
	Stroke Prevention in AF patients at High ICH Risk - Definition and Problems with Medical Management Edip Gurol, Harvard Medical School, USA Reversal Agents John Eikelboom, McMaster University, Canada Perils of Combination Anticoagulant and Antiplatelet Therapy Edip Gurol, Harvard Medical School, USA Resuming Anticoagulation after ICH Larry Goldstein, University of Kentucky, USA Panel Discussion
16:00	CLOSING CEREMONY

Registration Info

View Program